Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM
Not yet recruitingOBSERVATIONAL
Enrollment
500
Participants
Timeline
Start Date
July 1, 2025
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
Conditions
Colorectal Cancer Metastatic
All Listed Sponsors
lead
Peking University Cancer Hospital & Institute
OTHER
NCT07031570 - Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM | Biotech Hunter | Biotech Hunter